How does imiglucerase actually fix Gaucher disease inside my body?
Imiglucerase is a replacement enzyme that breaks down glucocerebroside, a fatty substance that builds up in Gaucher disease. When you receive IV infusions every 2 weeks, the enzyme enters your immune cells and macrophages, clearing the toxic buildup and shrinking enlarged organs by 30–60% within 6 months [6].
Gaucher disease happens when your body cannot make enough glucocerebrosidase enzyme, so fatty glucocerebroside piles up inside immune cells called macrophages. Imiglucerase is a man-made version of this missing enzyme, manufactured by Genzyme Corporation at 40 U/mL concentration. Clinical trials show that IV infusions every 2 weeks reduce spleen size by 40–60% and raise hemoglobin by 1–2 g/dL within 6 months [6][7].
Once imiglucerase enters your bloodstream during the IV infusion, it travels to macrophages in your spleen, liver, and bone marrow. The enzyme then breaks down glucocerebroside into simpler sugars and fats that your body can eliminate naturally. This cleanup process reduces organ swelling, eases bone pain, and restores normal blood counts—all because the enzyme is doing the job your own body cannot [2].
Real-world dosing depends on your body weight, organ size, and how quickly your spleen and hemoglobin respond. Most patients start at 60 U/kg every 2 weeks for 6 months, then may reduce to every 4 weeks if organs shrink and blood counts normalize [2]. Some patients with severe bone disease or very enlarged spleens need higher doses (120 U/kg) or longer infusion intervals to stay stable [5].
Ask your hematologist or genetic specialist to measure your spleen size by ultrasound and check your hemoglobin and ferritin levels before your first infusion. These baseline numbers help your doctor decide your starting dose and track whether imiglucerase is working over the first 3–6 months.